Hyperfractionated radiotherapy for high-proliferation NSCLC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm study conducted at a single center to evaluate safety and effectiveness of simultaneous integrated boost accelerated hyperfractionated radiotherapy in adults with high-proliferation NSCLC. The study will measure objective response rate, progression-free survival, and overall survival. Eligible participants are adults with confirmed high-proliferation NSCLC planned to receive thoracic radiotherapy, whether curative or palliative. Exclusion criteria include small cell histology, significant cardiac disease, pregnancy, concurrent interventional trials, or other conditions that may preclude enrollment. The lead sponsor is the Second Affiliated Hospital, Zhejiang University, School of Medicine, with activities taking place at the same institution in Hangzhou, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years, male or female;
2. Histologically or cytologically confirmed high-proliferation non-small cell lung cancer (NSCLC);
3. Assessed by a multidisciplinary team (MDT) and planned to receive thoracic radiotherapy (either curative or palliative), regardless of stage.

Exclusion Criteria:

1. Small cell histology;
2. Severe cardiac disease (New York Heart Association \[NYHA\] functional class ≥ III, uncontrolled arrhythmia, or myocardial infarction within the past 6 months);
3. Pregnant or breastfeeding women, or patients of childbearing potential who are unwilling to use effective contraceptive measures;
4. Concurrent participation in other interventional clinical trials;
5. Other conditions deemed by the investigator to make the patient unsuitable for enrollment (e.g., severe mental illness).

Where it's running

• 2nd Affiliated Hospital, School of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Ting Zhang — 2nd Affiliated Hospital, School of Medicine, Zhejiang University
• Study coordinator: Lu Wang
• Email: dluwang0727@163.com
• Phone: +86 057137826869

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.